312 73% 25

Interactive CME Video12/31/20 – 12/30/21

Have engaged with the content as of September 2021

Specialize in oncology or dermatology

Average number of patients with melanoma seen by completers per month

� Baseline knowledge was lowest regarding patient and tumor characteristics that guide clinical decision-making

� Completers needed further rationale to score above 75% on the posttest, suggesting that these topics continue to challenge providers

Clinical advances

Combinations and sequencing

Treatment selection

Challenging clinical scenarios

The majority has a positive perception of triple therapy

Most would use triple therapy for first-line treatment in BRAF-mutated disease

Most would use dual CPI after progression on first-line CPI

Only 19% would pursue triple therapy after progression on dual therapy

Learners lack consensus regarding treatment of early metastatic disease

Learners lack consensus regarding treatment of symptomatic, diffuse metastatic disease

Activity Overview

Participant Engagement

Impact on Knowledge and Persisting Gaps

Impact on Confidence

Perception of Triple Therapy

Insights – What Does this Mean for Future Education?

Practice Preferences for Patients With BRAF-Mutated Melanoma

Content Focused on BRAF-Mutated Melanoma

Current perception of triple therapy with BRAFi/MEKi + anti-PD1 in the first-line setting for advanced BRAF-mutated melanoma

VINDICOmedical education®

HealthNational Jewish

With the rapid evolution of treatments and combinations for the management of patients with advanced melanoma, oncology providers are challenged to stay current about the latest evidence-based recommendations for optimized patient care. To address this challenge, Vindico Medical Education and National Jewish Health delivered an engaging CME activity designed to both address these educational needs and elucidate treatment preferences as well persisting gaps in knowledge and confidence. Critical insights are highlighted below.

?

312 73% 25

Post-education mastery remained low, suggesting the need for further

knowledge- and skills-based learning to increase confidence

The number of learners who were guessing decreased as

those who were confident and correct increased

Guessing

Final Posttest

Pretest

3%

28%

Pretest Final Posttest

51%

9%

Mastery (confident and correct)

56%

30% 28%

62%

37%49%

88%79% 79%

Emergingcombinations

Latest clinical trialdata

Characteristics toinform decision-

making

Knowledge Scores by Topic

Pretest First posttest Final posttest

Positive; would recommend for eligible patients

Unsure Negative; safety concerns

50%More data

needed

28% 18% 3%N=125

First-line treatment

*Triple therapy: BRAFi/MEKi + anti-PD1 agent

N=125

BRAF-mutated melanoma with bone, liver, and CNS involvement

After progression on first-line CPI

After progression on dual-targeted therapy

Early, asymptomatic, metastatic disease

3%

17%

23%

14%

14%

29%

Sandwich

Ipi + Nivo to Triplet

Short course BRAFi/MEKi to Ipi + Nivo

Triplet

BRAFi/MEKi

Ipi + Nivo

9 The education reached a large audience of practicing oncology providers

9 There was an overall 101% relative increase in knowledge post-education and a robust increase in confidence

9 As recommendations and guidelines continue to evolve, oncology providers will require knowledge- and skills-based education on these topics

9 Despite the increase in knowledge, baseline and first posttest knowledge scores indicated persisting gaps in knowledge

9 While 49% of providers have a positive perception of triple therapy, they lack consensus regarding the use of combination approaches, particularly in relapsed cases and in patients with distant metastases

?

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

N=151 paired responses

ealio

9%

23%23%

45%

Anti-PD1 monotherapy

BRAFi/MEKiAnti-PD1 + Anti-CTLA-4

Triple therapy*

N=125


Anti-CTLA-4

Anti-PD1 + Anti-CTLA-4

Triple therapy*

17%

53%

19%

2%

9%

N=125

Clinical trial

16%

19%

51%

11% 3%Switch to alternative CPI

BRAFi/MEKi


Triple therapy*

N=125

Clinical trial



Triple therapy* Clinical trial

18%

15%21%

24%

24%

N=125

Clinical trial

BRAFi/MEKi

312 73% 25

Documents